|
Click here to view online. Add this email to your safelist. |
|||||||||||
|
|
|||||||||||
|
Agreement with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia completed |
|||||||||||
|
|
|||||||||||
|
16 December 2019
AstraZeneca has completed an agreement to divest its commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm Arzneimittel GmbH (Cheplapharm). |
|||||||||||
|